Haemonetics/$HAE

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Haemonetics

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Ticker

$HAE

Primary listing

NYSE

Industry

Health Care Equipment & Supplies

Employees

3,023

ISIN

US4050241003

Haemonetics Metrics

BasicAdvanced
$3.8B
23.62
$3.31
0.37
-

What the Analysts think about Haemonetics

Analyst ratings (Buy, Hold, Sell) for Haemonetics stock.

Bulls say / Bears say

Haemonetics' Plasma business continues to grow, driven by robust U.S. collection volume and double-digit increases in North America software and Europe disposable revenues. (nasdaq.com)
The company is progressing with the full market release of its new Express Plus technology, enhancing its competitive advantage in plasma collection. (nasdaq.com)
Haemonetics' hospital portfolio is evolving, creating new opportunities for growth and diversification, with each product line holding a leading market position. (nasdaq.com)
Haemonetics' stock hit a 52-week low of $70.1 amid challenges, reflecting market concerns about its financial performance and future prospects. (investing.com)
The company faced a downturn in its stock price following the release of its third-quarter earnings, which showed mixed results and led to lowered fiscal year 2025 growth guidance. (tipranks.com)
Analysts from firms like Raymond James, Mizuho, Barrington, JMP Securities, and BofA have reduced their price targets for Haemonetics, indicating concerns about the company's growth prospects. (tipranks.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.

Haemonetics Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Haemonetics Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $HAE

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs